MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555244 | Name: EG00229

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EG00229 is a Neuropilin 1 (NRP1) receptor antagonist. EG00229 inhibits VEGFA binding to NRP1.

Chemical Structure

EG00229
EG00229
CAS#1018927-63-3 (free base)

Theoretical Analysis

MedKoo Cat#: 555244

Name: EG00229

CAS#: 1018927-63-3 (free base)

Chemical Formula: C17H19N7O5S3

Exact Mass: 497.0610

Molecular Weight: 497.56

Elemental Analysis: C, 41.04; H, 3.85; N, 19.71; O, 16.08; S, 19.33

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1018927-63-3 (free base) 1210945-69-9 (TFA)
Synonym
EG00229; EG-00229; EG 00229;
IUPAC/Chemical Name
(3-(benzo[c][1,2,5]thiadiazole-4-sulfonamido)thiophene-2-carbonyl)-L-arginine
InChi Key
ZWWMEDURALZMEV-NSHDSACASA-N
InChi Code
InChI=1S/C17H19N7O5S3/c18-17(19)20-7-2-4-11(16(26)27)21-15(25)14-10(6-8-30-14)24-32(28,29)12-5-1-3-9-13(12)23-31-22-9/h1,3,5-6,8,11,24H,2,4,7H2,(H,21,25)(H,26,27)(H4,18,19,20)/t11-/m0/s1
SMILES Code
N=C(N)NCCC[C@@H](C(O)=O)NC(C1=C(NS(=O)(C2=CC=CC3=NSN=C32)=O)C=CS1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 497.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Powell J, Mota F, Steadman D, Soudy C, Miyauchi JT, Crosby S, Jarvis A, Reisinge T, Winfield N, Evans G, Finniear A, Yelland T, Chou YT, Chan AWE, O'Leary A, Cheng L, Liu D, Fotinou N, Milagre C, Martin JF, Jia H, Frankel P, Djordjevic S, Tsirka SE, Zachary IC, Selwood DL. Small molecule neuropilin-1 antagonists combine anti-angiogenic and anti-tumour activity with immune modulation through reduction of transforming growth factor beta (TGFβ) production in regulatory T-cells. J Med Chem. 2018 Apr 12. doi: 10.1021/acs.jmedchem.8b00210. [Epub ahead of print] PubMed PMID: 29648813. 2: Miyauchi JT, Chen D, Choi M, Nissen JC, Shroyer KR, Djordevic S, Zachary IC, Selwood D, Tsirka SE. Ablation of Neuropilin 1 from glioma-associated microglia and macrophages slows tumor progression. Oncotarget. 2016 Mar 1;7(9):9801-14. doi: 10.18632/oncotarget.6877. PubMed PMID: 26755653; PubMed Central PMCID: PMC4891085. 3: Nissen JC, Selwood DL, Tsirka SE. Tuftsin signals through its receptor neuropilin-1 via the transforming growth factor beta pathway. J Neurochem. 2013 Nov;127(3):394-402. doi: 10.1111/jnc.12404. Epub 2013 Sep 18. PubMed PMID: 24033337; PubMed Central PMCID: PMC3805743. 4: Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C, Hartzoulakis B, Nally J, Stewart M, Cheng L, Menon M, Tickner M, Djordjevic S, Driscoll PC, Zachary I, Selwood DL. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53(5):2215-26. doi: 10.1021/jm901755g. PubMed PMID: 20151671; PubMed Central PMCID: PMC2841442.